



Washington Metropolitan Society of Health-System Pharmacists Newsletter

President's Message

**Volume 2, Issue 2
February 2017**

WMSHP Executive Board

President

Justin Sebakijje, PharmD

President Elect

Ivan Cephas, PharmD

Immediate Past President

Vaiyapuri Subramaniam, PharmD

Treasurer

Joanne Woskov, PharmD

Secretary

Roberta Taylor, PharmD

Board Members

Dipti Kalra, RPh

Sadhna Khatri, PharmD

ASHP Delegates

Carla Darling, PharmD

Ashok Ramalingam, PharmD

Laura Zendel, PharmD

IT Support

Grace Hsu, PharmD

Mailing Address:

WMSHP

The UPS Store # 0478

P.O. Box 332

11006 Veirs Mill Rd, Ste L-15

Wheaton, MD 20902

Dear WMSHP Members,

February has been a very productive month for our society and I wanted to briefly touch upon some wonderful new developments, namely: WMSHP re-accreditation status, new committee appointments, and on-going initiatives.



WMSHP Re-Accreditation Status with ASHP – Officially Granted!

WMSHP has now been granted full re-accreditation status from ASHP for another term. We have been working diligently over the past few months with our executive board to meet and surpass all requirements. The Director of Affiliate Relations has confirmed that our society is in great shape and going forward we will continue to report quarterly all the necessary benchmarks for our continued success as an affiliate organization.

WMSHP New Committee Appointments – 12 Key Positions Filled!

WMSHP has been successful in the recruitment of an entire team dedicated to the advancement of our society. Namely, our six key committees are up and running and meeting monthly to address key initiatives tabled for discussion. All information is current and uploaded to our website for all interested parties to view. In addition, we continue to actively seek out new members who can volunteer time and join a committee to help meet the initiatives in our ever expanding 2017 agenda.

WMSHP New and On-Going Initiatives – *the 2017 Agenda!*

WMSHP members have been working tirelessly towards the advancement and growth of our society through new and innovative initiatives. These initiatives include, but are not limited to: modernizing our current constitution and bylaws to better reflect current practice (Legislative Committee), introducing a new student scholarship to encourage future pharmacy leaders

Continued on page 2

President's Message

Continued from page 1

(Nominations Committee), continuing our tradition of premier CE and Non-CE Events (Programming Committee), continued outreach to regional pharmacy schools such as the University of Maryland and Howard University (Membership Committee), keeping members abreast with current pharmacy issues through use of media such as our website and newsletter (Communications Committee), and exploring traditional and non-traditional revenue streams to remain fiscally sound (Finance Committee).

Warm regards and best wishes,

Justin Sebakijje, PharmD, BCPS

President, WMSHP

Clinical Capsule

Selexipag (Uptravi®, Actelion)

Selexipag is an oral selective prostacyclin IP receptor agonist. It is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Selexipag is initiated at 200 mcg twice daily, and may be increased by 200 mcg twice daily at weekly intervals. The maximum daily dose is 1600 mcg twice daily. Selexipag has not been studied in patients with eGFR <15 mL/min/1.73 m². In patients with moderate hepatic impairment, selexipag should be initiated at 200 mcg once daily, and may be increased by 200 mcg once daily at weekly intervals. Use should be avoided in patients with severe hepatic impairment.

Concomitant use of selexipag and strong CYP2C8 inhibitors may increase exposure to selexipag and its active metabolite, and should be avoided. Pulmonary edema can occur in patients with pulmonary veno-occlusive disease. Common adverse reactions include headache, diarrhea, jaw pain, nausea, myalgia, vomiting, pain in extremity, and flushing.

Uptravi® (selexipag) [package insert]. South San Francisco, CA : Actelion Pharmaceuticals US, Inc. ; 2015.

Upcoming Events

Statin Intolerance

(NON-CE Event)

Season 52
11414 Rockville Pike
North Bethesda, MD 20852

Wednesday, February 22, 2017
6:30 PM Registration & Dinner

Must RSVP WMSHP by
Monday, February 20, 2017

Email webwmsHP@gmail.com
or visit <http://wmsHP.org/event-registration.php>

Registration is closed

Reducing Readmission Rates

(NON-CE Event)

Location TBD

Tuesday, March 28, 2017
6:30 PM

Must RSVP WMSHP by
Sunday, March 26, 2017

Email webwmsHP@gmail.com
or visit <http://wmsHP.org/event-registration.php>

Photo Gallery



Outreach meeting with Howard University Alumni Association



Outreach meeting with the Washington DC Pharmacy Association